7D633B6ED617228D6CD702B2C9B6ED88

Scandonest® 3% Plain Mepivacaine HCl 3% Injection, USP Local dental anesthesia by infiltration or nerve block in adults and pediatric patients. Formulation without vaso-constrictor for specific medical situations. Fast onset: 30 to 120 seconds in the maxilla and 1 to 4 minutes for the mandible. Duration: will ordinarily provide pupal anesthesia of about 20 minutes in the maxilla, and about 40 minutes in the mandible. No-methlylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml cartridges. Total of (50) cartridges. Reactions to Scandonest® are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Scandonest® is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of mepivacaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Scandonest® 2% L contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.

7E121BEFB8AB131AA18C81AB76493231

Scandonest® 2% L Mepivacaine HCl 2% and Levonordefrin 1:20,000 Injection, USP Local dental anesthethesia by infiltration or nerve block in adults and pediatric patients. Mepivacaine provides anesthesia for longer duration for more prolonged procedures: in the maxilla the duration is 1 to 2.5 hours and 2.5 to 5.5 hours in the mandible. No-methlyparaben formulation to avoid allergic reactions on sensitive patients. 100% percent latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml glass cartridges. Total of (50) cartridges. Reactions to Scandonest® are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Scandonest® is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of mepivacaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Scandonest® 2% L contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.

Top Seller
4F32A0A785CBEA10144237F1B07DBDBE

Local dental anesthesia in both simple and complex dental procedures. Septocaine and epinephrine 1:100,000 is preferred during operative or surgical procedures when improved visualization of the surgical field is desirable. Fast onset (1 to 9 minutes) to avoid delay before effective analgesia is achieved. Predictable duration of anesthesia: up to 60 minutes for infiltration injections and 120 minutes for nerve blocks. No-methylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml cartridges. Total of (50) cartridges. Septocaine® is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. Septocaine® and epinephrine 1:100,000 is preferred during operative or surgical procedures when improved visualization of the surgical field is desirable. Reactions to Septocaine® (pain and headache, for example, or convulsions or respiratory arrest following accidental intravascular injection) are characteristic of those associated with other amide-type local anesthetics. Septocaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Accidental intravascular injection may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners and/or clinicians who employ local anesthetic agents should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Septocaine®, along with other local anesthetics, is capable of producing methemoglobinemia. The clinical signs of methemoglobinemia are cyanosis of the nail beds and lips, fatigue and weakness. If methemoglobinemia does not respond to administration of oxygen, administration of methylene blue intravenously 1-2 mg/kg body weight over a 5 minute period is recommended. Please see the Package Insert for prescribing information.

Top Seller
Top Seller
42AB65877D3DFFC8829FE340E49B3E36

Local dental anesthesia in both simple and complex dental procedures. For most routine dental procedures Septocaine 1:200,000 is preferred. Fast onset (1 to 9 minutes) to avoid delay before effective analgesia is achieved. Predictable duration of anesthesia: up to 60 minutes for infiltration injections and 120 minutes for nerve blocks. No-methylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Includes: (5) Blisters of (10) 1.7ml cartridges. Total of (50) cartridges. Septocaine® is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. Septocaine® and epinephrine 1:100,000 is preferred during operative or surgical procedures when improved visualization of the surgical field is desirable. Reactions to Septocaine® (pain and headache, for example, or convulsions or respiratory arrest following accidental intravascular injection) are characteristic of those associated with other amide-type local anesthetics. Septocaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Accidental intravascular injection may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners and/or clinicians who employ local anesthetic agents should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Septocaine®, along with other local anesthetics, is capable of producing methemoglobinemia. The clinical signs of methemoglobinemia are cyanosis of the nail beds and lips, fatigue and weakness. If methemoglobinemia does not respond to administration of oxygen, administration of methylene blue intravenously 1-2 mg/kg body weight over a 5 minute period is recommended. Please see the Package Insert for prescribing information.

Top Seller
924DA3CFBA5321C9C45760842E0CE1D7

Vivacaine® Bupivacaine HCl 0.5% and Epinephrine 1:200,000 Injection, USP Local dental anesthesia by infiltration or nerve block injections in adults. Anesthesia may last two to three times longer than lidocaine and mepivacaine for dental use, in many patients up to 7 hours. Onset of action is usually 2 to 10 minutes. No-methlyparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml glass cartridges. Total of (50) cartridges. Reactions to Vivacaine® are characteristic of those used with other amide-type local anesthetics. A major cause of reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Vivacaine® is contraindicated in patients with a known hypersensitivity to it or any local anesthetic agent of the amide type or to other components of Vivacaine® solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, an the personnel resources needed for proper management of toxic reactions and related emergencies. Vivacaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please seen the Package Insert for prescribing information.

Top Seller
Top Seller
435406D9BF3C09743C74E50EFC65F851
Top Seller
Top Seller
Top Seller
Top Seller
1905472982AE7A1ACED7FA84C58C8D18

Carbocaine® 3% Mepivacaine and Levonordefrin Injection, USP without vasoconstrictor Local dental anesthesia by infiltration or nerve block in adults and pediatric patients. Formulation without vaso-constrictor for specific medical situations. Fast onset: 30 to 120 seconds in the maxilla and 1 to 4 minutes for the mandible. Duration: will ordinarily provide pulpal anesthesia of about 20 minutes in the maxilla.and about 40 minutes in the mandible. No-methylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml glass cartridges. Total of (50) cartridges. Reactions to Carbocaine® are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Carbocaine® is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of mepivacaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Carbocaine® 2% L contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.

1EB081E820C390D294922B219ECC9A29

Carbocaine® 2% with Neo-Cobefrin® Mepivacaine and Levonordefrin Injection, USP Local dental anesthesia by infiltration or nerve block in adults and pediatric patients. Mepivacaine provides anesthesia for longer duration for more prolonged procedures: in the maxilla the duration is 1 to 2.5 hours and 2.5 to 5.5 hours in the mandible. No-methlyparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml glass cartridges. Total of (50) cartridges. Reactions to Carbocaine® are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Carbocaine® is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of mepivacaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Carbocaine® 2% L contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.

Top Seller
883A31D14EEAE745B26951B3B0E1C3C5

Marcaine® Bupivacaine HCl 0.5% and Epinephrine 1:200,000 Injection, USP No-methylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml glass cartridges. Total of (50) cartridges. Reactions to Marcaine® are characteristic of those used with other amide-type local anesthetics. A major cause of reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Marcaine® is contraindicated in patients with a known hypersensitivity to it or any local anesthetic agent of the amide type or to other components of Marcaine® solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, an the personnel resources needed for proper management of toxic reactions and related emergencies. Marcaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please seen the Package Insert for prescribing information.

678AAEC0AF0E37D7D8D0DD3C2E261A85

Zorcaine™ Articaine HCl 4% and Epinephrine 1:100,000 Injection Local dental anesthesia in both simple and complex dental procedures. Zorcaine and epinephrine 1:100,000 is preferred during operative or surgical procedures when improved visualization of the surgical field is desirable. Fast onset (1 to 9 minutes) to avoid delay before effective analgesia is achieved. Predictable duration of anesthesia: up to 60 minutes for infiltration injections and 120 minutes for nerve blocks. No-methylparaben formulation to avoid allergic reactions on sensitive patients. 100% latex free components to help reduce allergic responses. Terminal sterilization of product/cartridges for safe use. Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage. Includes: (5) Blisters of (10) 1.7ml cartridges. Total of (50) cartridges. Articaine is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. Articaine and epinephrine 1:100,000 is preferred during operative or surgical procedures when improved visualization of the surgical field is desirable. Reactions to Articaine (pain and headache, for example, or convulsions or respiratory arrest following accidental intravascular injection) are characteristic of those associated with other amide-type local anesthetics. Articaine contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Accidental intravascular injection may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners and/or clinicians who employ local anesthetic agents should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Articaine, along with other local anesthetics, is capable of producing methemoglobinemia. The clinical signs of methemoglobinemia are cyanosis of the nail beds and lips, fatigue and weakness. If methemoglobinemia does not respond to administration of oxygen, administration of methylene blue intravenously 1-2 mg/kg body weight over a 5 minute period is recommended. Please see the Package Insert for prescribing information.